Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients
Authors:
Open Access
- 30 November 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (67) , 111246-111257
Abstract
Https://doi.org/10.18632/oncotarget.22768 Jian Su, Wenzhao Zhong, Xuchao Zhang, Ying Huang, Honghong Yan, Jinji Yang, Zhongyi Dong, Zhi Xie, Qing Zhou, Xiaosui Huang, Danxia Lu, Wenqing Yan, Yi-Long WuKeywords
This publication has 25 references indexed in Scilit:
- Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinibOncoTargets and Therapy, 2012
- Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical ImplicationsPLOS ONE, 2012
- Clinical Outcomes in Non–Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFRClinical Cancer Research, 2012
- EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung AdenocarcinomaClinical Cancer Research, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential SensitivityJournal of Thoracic Oncology, 2012
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Clinical screening assay for EGFR exon 19 mutations using PNA-clamp smart amplification process version 2 in lung adenocarcinomaOncology Reports, 2011
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsOncogene, 2009
- Detection of Mutations inEGFRin Circulating Lung-Cancer CellsNew England Journal of Medicine, 2008